This health technology company offers advanced liquid biopsy analysis of cell-free DNA to monitor treatment response. Their platform provides healthcare providers with non-invasive methods for personalized patient care and disease insights.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional methods for monitoring treatment response and understanding disease progression often involve invasive procedures. These methods can be limiting due to their complexity, cost, and the potential risks associated with tissue biopsies. This creates a need for non-invasive, accessible methods to gain insights into human biology and personalize patient care.
Solution
LiquidCell Dx offers a platform for advanced liquid biopsy analysis of cell-free DNA (cfDNA), providing unprecedented insights into health and disease. Their technology extracts and analyzes cfDNA from simple blood samples, overcoming the limitations of traditional methods. By measuring and analyzing cfDNA, the platform enables monitoring of treatment response, understanding of disease processes, and personalized care for patients. The platform's advanced liquid biopsy technology offers a non-invasive approach to gain a deeper understanding of human biology and disease.
Target Audience
The primary users are healthcare providers and clinical researchers seeking non-invasive methods for personalized patient care, disease monitoring, and gaining insights into human biology.
Features
- Advanced liquid biopsy technology for extracting insights from cell-free DNA.
- Non-invasive method using simple blood samples.
- Analysis of cell-free DNA to monitor treatment response.
- Platform designed to overcome limitations of traditional methods.